Revere Biotech Pipeline Risk Reports ::

Revere Biotech Pipeline Risk Reports allow investors to more completely monitor and evaluate three key markers for biotech companies -- their pipelines, the competitive landscape of their products' mechanisms of action, and portfolio exposure levels.

Success or failure for biotech companies often depends on one or two products.  By focusing on the impact of these three markers, biotech investors can better manage their risk exposure through understanding the level of diversification for each and as a whole. The Revere Biotech Pipeline Risk Report  addresses these diversification issues by identifying companies that have:
  • One or more drug candidates utilizing a mechanism of action already approved by the FDA
  • One or more drug candidates facing two or fewer alternative drugs with the same mechanism of action for the same indication
  • An established strategic partnership with one or more blue-chip biopharmaceutical companies
  • Market cap between $50 Million and $1 Billion

Sample individual reports:

Individual Biotech Pipeline Risk Reports are available in our e-commerce store located at www.reveredata.com/reports/store .